Aspirin Use and Gastric Adenocarcinoma-Letter
Cancer Prev Res (Phila)
.
2022 Aug 1;15(8):553.
doi: 10.1158/1940-6207.CAPR-22-0260.
Authors
Shih-Wei Lai
1
2
,
Bing-Fang Hwang
3
,
Chiu-Shong Liu
4
2
,
Kuan-Fu Liao
5
6
Affiliations
1
Department of Public Health, College of Public Health, and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
2
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.
3
Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan.
4
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
5
College of Medicine, Tzu Chi University, Hualien, Taiwan.
6
Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan.
PMID:
35912408
DOI:
10.1158/1940-6207.CAPR-22-0260
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenocarcinoma* / prevention & control
Aspirin / therapeutic use
Gastric Mucosa
Humans
Stomach Neoplasms* / prevention & control
Substances
Aspirin